Custom service

Anti-Hapten Antibody Production

Small molecules made immunogenic, without losing the epitope that matters.

Hapten size: <1,000 Da — typically 200–500 DaCarriers: KLH, BSA, OVA — plus BTG and thyroglobulinTimeline: 12–16 weeks — to competitive ELISA

A molecule below about 1,000 Da cannot cross-link B cell receptors, so it cannot provoke an immune response on its own. The solution is old and reliable: couple it to a carrier protein, immunise with the conjugate, and then screen for antibodies that recognise the free hapten. What makes the work difficult is not the coupling but the chemistry that preserves the part of the molecule the assay needs to detect.

Coupling consumes a functional group. If the hapten has a single carboxylate and that carboxylate is what distinguishes it from its metabolite, EDC/NHS coupling to carrier lysines will produce an antibody that no longer sees the difference. The conjugation strategy is therefore chosen against the structure: carboxylate via EDC/NHS, amine via glutaraldehyde or succinic anhydride, thiol via maleimide, hydroxyl via periodate oxidation, and aromatic rings via diazotisation.

Screening is competitive by necessity. A hapten cannot be coated on a plate in a way that allows two antibodies to sandwich it, so the assay format is competition between immobilised hapten-carrier conjugate and free analyte in solution. The readout is the hapten concentration that inhibits binding by 50%, and it is measured against structural analogues to establish specificity.

Service Highlights

Where it fits

Anti-hapten antibodies underpin immunoassays for drugs of abuse, therapeutic drug monitoring, pesticide and veterinary residues, mycotoxins and small-molecule biomarkers. They are also used as capture reagents in competitive formats where the analyte is too small for a sandwich pair.

The approach struggles when the hapten has no suitable functional group for selective coupling, or when the analyte is metabolised rapidly and the antibody must distinguish a metabolite that differs by a single hydroxyl. In those cases a structurally informed immunogen design — or an anti-idiotype against a specific conformer — is usually required.

Documentation and QC

Each clone or lot is delivered with a competitive standard curve, IC50, and a cross-reactivity matrix covering structural analogues and metabolites. Conjugation ratio of the coating antigen is reported, because an assay's specificity can be shifted by the density of hapten on the plate.

Frequently asked questions

Why is the antibody screened by competition rather than direct binding?

A small hapten presents too few epitopes for a sandwich. Coating the hapten-carrier conjugate and competing with free analyte is the only format that measures recognition of the molecule rather than of the carrier or the spacer.

Can you make an antibody against a metabolite?

Yes, provided the metabolite can be synthesised or obtained in sufficient purity. The coupling site is chosen so that the distinguishing functional group stays free, which usually means coupling through a position remote from the modification.

How specific can a small-molecule antibody be?

Routinely able to distinguish compounds differing by one hydroxyl or one methyl group, with cross-reactivity below 5%. Achieving that depends more on the immunogen design than on the screening effort.

Send the structure and the analogues you need to discriminate. The conjugation strategy follows from that, and we will confirm it is feasible before any synthesis begins.

Service Highlights

  • Structure-led conjugation. The coupling site is selected to leave the immunodiscriminating part of the molecule exposed, with the rationale documented.
  • Hapten density control. 5–20 haptens per carrier molecule, measured by MALDI-TOF or TNBS assay; over-conjugation suppresses the anti-hapten response.
  • Multiple carrier options. KLH for immunisation, BSA or OVA for screening, so carrier-specific clones are identified and removed early.
  • Competitive ELISA screening. IC50 and cross-reactivity against analogues, metabolites and structurally related compounds.
  • Monoclonal or polyclonal. Mouse monoclonals for reproducible immunoassays, rabbit polyclonals for broad recognition of a compound class.
  • Antibody against small molecules in matrix. Tolerance testing in serum, urine or food extract, since matrix effects decide whether an assay works outside buffer.

How the work runs

  1. Hapten and analogue review

    The structure is examined for functional groups and for the region that distinguishes the analyte from its analogues. This determines both the coupling chemistry and the spacer length.

  2. Conjugation and characterisation

    Coupling through the chosen group with a 3–6 carbon spacer; conjugation ratio measured by MALDI-TOF, and free hapten removed by dialysis or SEC.

  3. Immunisation

    Four to five injections of 100–200 µg conjugate. Because the carrier dominates the response, two carriers are sometimes used in alternating injections.

  4. Competitive screening

    Supernatants screened by competition ELISA: immobilised hapten-OVA versus free hapten. Carrier-specific and spacer-specific binders are removed at this step.

  5. Specificity profiling

    IC50 against the target and against 5–15 analogues, giving a cross-reactivity matrix that is reported in full.

  6. Cloning and assay transfer

    Subcloning, isotyping, then format transfer to the intended platform — ELISA, lateral flow or CLIA — with a working standard curve.

Specifications & timeline

Hapten size
<1,000 Da — typically 200–500 Da
Carriers
KLH, BSA, OVA — plus BTG and thyroglobulin
Timeline
12–16 weeks — to competitive ELISA
Hapten size
Typically 150–1,000 Da; smaller molecules require a longer spacer
Carriers
KLH, BSA, OVA, BTG, thyroglobulin
Coupling chemistry
EDC/NHS, glutaraldehyde, maleimide, periodate, diazotisation, click chemistry
Hapten density
5–20 mol hapten per mol carrier, verified by MALDI-TOF
Screening
Competitive ELISA with IC50 and full cross-reactivity matrix
Deliverables
2–5 monoclonals or 10–50 mg polyclonal IgG, conjugate standards, assay protocol

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.